



**RaQualia**  
innovators for life

**EP<sub>4</sub> Receptor Antagonist for  
Autoimmune Diseases and Allergy**  
**Worldwide Partnering Opportunity**

# 1. Executive Summary

- Potent and selective EP4 antagonists in Phase 2 and non-clinical stage
  - RQ-00000007: Proof of concept in osteoarthritis (OA) pain in two Phase 2a studies
  - RQ-00000008: Completed non-clinical profiling, i.e., safety pharmacology, DMPK, and toxicology studies, for Phase 1 studies
  - Back-up compounds: Non-clinical stage
  
- EP4 antagonists
  - Inhibit PGE<sub>2</sub>-induced IL-23 production in dendritic cells and PGE<sub>2</sub> / ConA-induced IL-6 production in PBMC *in vitro*
  - Exhibit efficacy in animal models of inflammatory bowel disease (IBD), allergic contact dermatitis, and adjuvant arthritis
  - Provide attractive opportunities for the treatment of autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, IBD, and multiple sclerosis (MS) and type IV allergic diseases

## 2. Table of Contents

Title	Slide No.
1. Executive Summary	2
2. Table of Contents	3
3. PGE <sub>2</sub> -EP4 Signaling: Immune Activation and Autoimmune / Type IV Allergic Diseases	4
4. Down Stream to PGE <sub>2</sub> -EP4 Signaling	5
5. Pro-Inflammatory Signaling via PGE <sub>2</sub> -EP <sub>4</sub> Receptor	6
6. PGE <sub>2</sub> -EP4 Signaling: Immune Activation	
7. Non-Clinical Pharmacology	7
7.1. <i>In vitro</i> Pharmacology Summary	8
7.2. IL-23 Production in Mouse CD11c (+) Cells	9
7.3. IL-17 Production in Mouse IL-17 (+) Cells	10
7.4. IL-6 Production in Human PBMC	11
7.5. Dextran Sulfate Sodium (DSS)-Induced Colitis Model in Mice	12
7.6. DSS-Induced Colitis in Mice	13
7.7. Picryl Chloride (PCI)-Induced Contact Hypersensitivity (CHS) Model in Mice	14
7.8. PCI-Induced CHS in Mice	15
7.9. Adjuvant-Induced Arthritis Model in Rats	16
7.10. Paw Swelling on Adjuvant-Induced Arthritis in Rats	17-20
8. Potential Indications for EP4 Antagonist	21
9. References	22-24
<b>Appendix</b>	
10. Compound Information and Non-Clinical Results of RQ-00000007	26-33
11. Clinical Studies and Results of RQ-00000007	34-38
12. Compound Information and Non-Clinical Results of RQ-00000008	39-43
13. Competitor Status	44
14. Publication List of RQ-00000007	45

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011